We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. government has struck a $375 million deal with Eli Lilly for 300,000 vials of its investigational COVID-19 treatment, LY-CoV555 (bamlanivimab). Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients. Read More
Novavax has announced that it will start a late-stage clinical trial of its investigational COVID-19 vaccine in the U.S. by the end of November. Read More
Pfizer CEO Albert Bourla announced Tuesday that the company won’t have the necessary phase 3 trial data required to submit its COVID-19 vaccine candidate for Emergency Use Authorization (EUA) this month, despite previous projections. Read More
AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Read More
An Indian trial evaluating convalescent plasma as a COVID-19 treatment has found that the therapy failed to reduce progression to severe COVID-19 or death, leaving the Indian government skeptical about its viability, though medical experts say the treatment may still hold promise. Read More